Hemoperfusion with a polymer or carbon hemoperfusion column is feasible and safe in goats.

Hemoperfusion is feasible and safe in goats but requires higher heparin doses than other species.

This prospective experimental study evaluated the feasibility and safety of hemoperfusion in healthy adult goats using two adsorptive column types: a polymer-based column (VetResQ) and a carbon-based column (Cytoclear). Four goats from the Texas A&M research herd underwent single hemoperfusion sessions processing two blood volumes, with one goat completing an additional session at one blood volume. The procedure was well tolerated with no major adverse events reported. A notable finding was the requirement for a significantly higher activated clotting time target (700–900 seconds) compared to other species, necessitating higher heparin doses to maintain consistent extracorporeal blood flow. Hematologic parameters, including transient decreases in WBC and neutrophil counts during filtration, returned to baseline within 24 hours. Moderate reductions in total protein, albumin, and potassium were observed but remained within reference ranges. Importantly, pro-inflammatory cytokines IL-1β and TNF-α decreased following treatment with both column types, while IL-10 showed no concerning elevations, suggesting an anti-inflammatory effect without inducing a cytokine storm. These results indicate that hemoperfusion is both feasible and apparently safe in caprine patients, establishing baseline data to support future investigations. The authors propose hemoperfusion as a potential therapeutic modality in goat medicine for conditions involving circulating toxins or excessive inflammatory mediators, such as sepsis, toxicoses, or systemic inflammatory response syndrome.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.